Gordon D S
Dev Biol Stand. 1977;38:567-72.
The Southeastern Cancer Study Group has been particularly interested in the use of immunological adjuvants in the treatment of melanoma and acute myelogenous leukemia. A study of chemotherapy versus chemoimmunotherapy in randomly selected patients with metastatic malignant melanoma revealed no significant increase in either complete remissions or overall survival in the group receiving chemoimmunotherapy. Preliminary results in a study involving maintenance of patients with acute myelogenous leukemia (chemotherapy versus chemoimmunotherapy) revealed suggestive but not statistically significant increases in remission duration and survival in the group receiving immunotherapy. Data from these ongoing studies and plans for new group studies are presented in this paper.
东南癌症研究小组一直对免疫佐剂在黑色素瘤和急性髓性白血病治疗中的应用特别感兴趣。一项针对随机选择的转移性恶性黑色素瘤患者进行的化疗与化疗免疫疗法对比研究显示，接受化疗免疫疗法的组在完全缓解率或总生存率方面均未出现显著提高。一项涉及急性髓性白血病患者维持治疗（化疗与化疗免疫疗法）的研究初步结果显示，接受免疫疗法的组在缓解期和生存率方面有提高的迹象，但未达到统计学显著水平。本文展示了这些正在进行的研究的数据以及新的组内研究计划。
